FDA Approves Another Tumor-Agnostic Cancer Drug

13:27 EDT 15 Aug 2019 | Medscape

Entrectinib is indicated for the treatment of solid tumors expressing NTRK+ in adults and children, and also for the treatment of metastatic, ROS1-positive non-small cell lung cancer
FDA Approvals

Original Article: FDA Approves Another Tumor-Agnostic Cancer Drug


More From BioPortfolio on "FDA Approves Another Tumor-Agnostic Cancer Drug"

Quick Search

Relevant Topics

Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...